In a study, the link between CpG methylation signature and MYCN amplification status was investigated in a total of 126 NB samples, inclusive of 45 MYCN-amplified and 81 non-MYCN-amplified datasets deposited to therapeutically applicable research to generate effective treatment (TARGET); from these datasets, 396,065 CpGs were retrieved [37]. This evidence concerns the gene MYCN and neuroblastoma.